Product Information
DEFERASIROX 360 MG TABLET is a generic product labeled by Ascend Laboratories, LLC, priced at $1.3399 per EA under NDC 67877055430. Its NADAC has been published 223 times since Apr 20, 2022.
FDA first approved this application on Mar 30, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Deferasirox market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
360 mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877055430
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
DEFERASIROXApproval Type
Generic (ANDA)
FDA Application
ANDA210555FDA Approved
3/30/2020
TE Code
AB
On Market Since
4/1/2020
Pharmacological Classes
Price Statistics
The NADAC for DEFERASIROX 360 MG TABLET has been published 223 times since Apr 20, 2022, and over the history we have for it it has declined 36.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3399 per EA |
|---|---|
| All-time high | $2.1034 (Apr 12, 2023) |
| All-time low | $1.2249 (Nov 19, 2025) |
| 52-week high | $1.6434 |
| 52-week low | $1.2249 |
| Median price | $1.9511 |
| Average price | $1.7763 |
| Largest weekly change | +29.6% (Mar 18, 2026) |
| Weeks tracked | 223 |
| Tracking since | Apr 20, 2022 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of DEFERASIROX 360 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DEFERASIROX 360 MG TABLET, manufactured by Ascend Laboratories, LLC, is $1.3399 per EA (NDC 67877055430), effective Aug 19, 2026.
How has the price of DEFERASIROX 360 MG TABLET changed over time?
Over the history we have for it, the NADAC for DEFERASIROX 360 MG TABLET has declined 36.3%. It has been tracked across 223 weekly CMS publications since Apr 20, 2022.
What are the highest and lowest recorded NADAC prices for DEFERASIROX 360 MG TABLET?
Since Apr 20, 2022, the NADAC for DEFERASIROX 360 MG TABLET has ranged from a low of $1.2249 (Nov 19, 2025) to a high of $2.1034 (Apr 12, 2023), with a median of $1.9511 per EA.
Are there cheaper alternatives to DEFERASIROX 360 MG TABLET?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DEFERASIROX 360 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures DEFERASIROX 360 MG TABLET?
DEFERASIROX 360 MG TABLET (NDC 67877055430) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.